GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹109 Cr | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹109 Cr |
| Mar2024 | ₹-357 Cr |
| Mar2023 | ₹2,621 Cr |
| Mar2022 | ₹1,270 Cr |
| Mar2021 | ₹2,804 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹109 Cr | Positive | |
| Mar2024 | ₹-357 Cr | Negative | |
| Mar2023 | ₹2,621 Cr | 106.48 | |
| Mar2022 | ₹1,270 Cr | -54.72 | |
| Mar2021 | ₹2,804 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹67,097.3 Cr | 1.6% | 6.6% | 66.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,195.0 Cr | 0.9% | 12.7% | 8.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹182,993.0 Cr | -0.4% | 9.7% | 11.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,926.0 Cr | 0.5% | 5.8% | 36.5% | Stock Analytics | |
| CIPLA | ₹113,052.0 Cr | -2.7% | 13.9% | -6.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹110,333.0 Cr | 1.5% | 7.3% | 8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1.6% |
6.6% |
66.3% |
| SENSEX | 1% |
-4.1% |
-7.4% |
You may also like the below Video Courses